- Joined
- Nov 18, 1999
- Messages
- 2,600
- Reaction score
- 3,476
Irving Kirsch made a huge deal a decade or so ago with a claim that the effect of SSRIs was all placebo, that the apparent benefit over placebo was all related to functional unblinding, and would be eliminated if active placebos (i.e. non-SSRI drugs that had comparable subjective side effects) were used. Spoiler, that turned out not to be true.Why does this only seemingly matter in psychedelic studies? I highly doubt people can't tell the difference between Zyprexa and docusate or whatever placebo we use in those studies.
For MDMA it's an even weirder claim. The subjective effect *is the point*. If you could recreate it with a different agent, absolutely, it would likely work just as well. What would it mean to call this a placebo effect?
I agree that looking at only MDMA-naive patients certainly is helpful in addressing this concern, no doubt. But at the end of the day if participants can clearly tell they were in the treatment condition, there is a huge risk that they are going to answer questions in a way consistent with bigger symptom reduction than otherwise. Difficult as it is to do I think more studies with active placebos are desperately needed. I do understand the concerns that this may prove impossible to do perfectly but getting closer would help a lot.
The placebo arm was a below- threshold dose of the same drug. What would you suggest to use as a more appropriate active placebo?